Adjuvant Immunomodulatory (IM) Therapy
Phase 3Recruiting 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Mucopolysaccharidosis IIIA
Conditions
Mucopolysaccharidosis IIIA, MPS IIIA, Sanfilippo Syndrome, Sanfilippo A
Trial Timeline
Sep 28, 2020 → Aug 1, 2027
NCT ID
NCT04360265About Adjuvant Immunomodulatory (IM) Therapy
Adjuvant Immunomodulatory (IM) Therapy is a phase 3 stage product being developed by Ultragenyx Pharmaceutical for Mucopolysaccharidosis IIIA. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04360265. Target conditions include Mucopolysaccharidosis IIIA, MPS IIIA, Sanfilippo Syndrome.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04360265 | Phase 3 | Recruiting |
Competing Products
20 competing products in Mucopolysaccharidosis IIIA